Aptevo Therapeutics Inc APVO:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
3.04quote price arrow up+0.09 (+3.05%)
Volume
22,423
52 week range
2.90 - 22.08
Loading...
  • Open2.97
  • Day High3.29
  • Day Low2.97
  • Prev Close2.95
  • 52 Week High22.08
  • 52 Week High Date11/23/21
  • 52 Week Low2.90
  • 52 Week Low Date09/29/22

Key Stats

  • Market Cap15.47M
  • Shares Out5.09M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta5.62
  • YTD % Change-61.37

KEY STATS

  • Open2.97
  • Day High3.29
  • Day Low2.97
  • Prev Close2.95
  • 52 Week High22.08
  • 52 Week High Date11/23/21
  • 52 Week Low2.90
  • 52 Week Low Date09/29/22
  • Market Cap15.47M
  • Shares Out5.09M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta5.62
  • YTD % Change-61.37

RATIOS/PROFITABILITY

  • EPS (TTM)1.16
  • P/E (TTM)2.62
  • Fwd P/E (NTM)-0.44
  • EBITDA (TTM)-20.889M
  • ROE (TTM)34.19%
  • Revenue (TTM)9.88M
  • Gross Margin (TTM)26.40%
  • Net Margin (TTM)63.92%
  • Debt To Equity (MRQ)18.91%

EVENTS

  • Earnings Date11/09/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aptevo Therapeutics Inc

 

Profile

MORE
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. It has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular...
John Niederhuber M.D.
Independent Chairman of the Board
Marvin White
President, Chief Executive Officer, Director
Jeffrey Lamothe
Chief Financial Officer, Executive Vice President
Address
2401 4th Ave Ste 1050
Seattle, WA
98121-3460
United States